Treatment of Chronic Hepatitis B - Harrison's 22nd Edition (2025)

Overview and Goals of Therapy

• Clinical progression and hepatic decompensation
• HCC development
• Need for liver transplantation and death
• Regression of cirrhosis and esophageal varices has been documented with long-term pharmacologic suppression

Approved Drugs

Historical / Early-Generation Agents (No Longer Preferred)

Standard Interferon-alpha (IFN-alpha)

• First approved therapy (1992); no longer used for hepatitis B
• In HBeAg-reactive chronic hepatitis B: 16-week course (5 MU daily or 10 MU thrice weekly SC)
• Achieved loss of HBeAg and HBV DNA suppression in ~30%; HBeAg-to-anti-HBe seroconversion in ~20%; HBsAg loss in ~8%

Lamivudine (100 mg/day orally)

• First oral antiviral for hepatitis B
• In HBeAg-reactive CHB: HBeAg seroconversion in ~16-18% at 1 year; HBV DNA suppression to undetectable in ~40-44%
• In HBeAg-negative CHB: HBV DNA suppression in ~60-73%
• Major limitation: High rate of resistance (YMDD mutations) - ~15-30% per year; up to ~70% at 5 years
• No longer recommended as first-line therapy

Adefovir Dipivoxil (10 mg/day)

• Active against lamivudine-resistant HBV
• HBeAg seroconversion in ~12% at 1 year; HBV DNA undetectable in ~21% (HBeAg-positive)
• HBV DNA undetectable in ~51% at 1 year (HBeAg-negative)
• Resistance ~0% at 1 year, ~29% at 5 years
• Superseded by more potent agents

Telbivudine (600 mg/day)

• More potent than lamivudine but high resistance rates; no longer favored

Current First-Line Treatment Options

Pegylated Interferon (PEG IFN)

• PEG IFN alpha-2a 180 mcg/week SC x 48 weeks (for both HBeAg-positive and HBeAg-negative CHB)

• Finite treatment duration (48 weeks)
• No resistance
• Higher rates of HBsAg loss compared to nucleos(t)ides
• Off-therapy immune control sustained in some patients

• HBeAg seroconversion: ~27% vs ~20% with lamivudine at end of follow-up
• HBV DNA <400 copies/mL: ~14% vs ~7%
• HBsAg loss: ~3-4% vs ~0%

• HBV DNA suppression (PCR-undetectable) at end of treatment: ~63%
• Sustained response at 24 weeks post-treatment: ~19-20%

• Substantial side effect profile (flu-like symptoms, cytopenia, psychiatric effects, autoimmune)
• Contraindicated in cirrhosis (risk of sepsis and hepatic decompensation)
• Should not be used in decompensated liver disease
• Requires weekly injections; costly

• HBV genotype A responds best; genotype D responds least
• Low baseline HBV DNA, elevated ALT, active histology
• Declines in HBsAg levels during treatment (e.g., HBsAg <1500 IU/mL at week 12 for genotype A/D) are useful stopping rules

Entecavir (ETV)

• Dose: 0.5 mg/day orally (treatment-naive); 1.0 mg/day for lamivudine-refractory patients
• Potent nucleoside analogue, very low resistance profile

• HBV DNA undetectable (<300 copies/mL): ~67% vs ~36%
• Histologic improvement: ~72% vs ~62%
• HBeAg seroconversion: ~21% vs ~18%
• ALT normalization: ~68% vs ~60%

• HBV DNA undetectable: ~90% at 48 weeks

Tenofovir Disoproxil Fumarate (TDF)

• Dose: 300 mg/day orally
• Active against both wild-type and lamivudine-resistant HBV

• HBV DNA undetectable (<400 copies/mL): ~76% vs ~13%
• Histologic improvement: ~74% vs ~68%
• HBeAg seroconversion: ~21% vs ~18%

• HBV DNA undetectable: ~93% at 48 weeks vs ~63% with adefovir

Tenofovir Alafenamide (TAF)

• Dose: 25 mg/day orally
• Prodrug of tenofovir with improved safety profile; results in lower systemic tenofovir exposure

• HBeAg-positive: HBV DNA undetectable at 48 weeks: ~64% (TAF) vs ~67% (TDF)
• HBeAg-negative: HBV DNA undetectable at 48 weeks: ~94% (TAF) vs ~93% (TDF)
• HBeAg seroconversion rates similar

• Significantly less renal toxicity
• Better preservation of bone mineral density
• Preferred over TDF in: HIV-HBV co-infection, renal impairment, osteoporosis/osteopenia, elderly patients

Indications for Treatment

HBeAg-Positive Chronic Hepatitis B:

• HBV DNA >20,000 IU/mL AND ALT elevated (>2x ULN)
• Or any level of HBV DNA with evidence of significant liver disease (biopsy-proven moderate-severe hepatitis or cirrhosis)

HBeAg-Negative Chronic Hepatitis B:

• HBV DNA >2,000 IU/mL AND ALT elevated
• Lower thresholds considered if liver biopsy shows significant disease

Immune-Tolerant Phase (HBeAg+, very high HBV DNA, normal ALT):

• Generally treatment is deferred in the immune-tolerant phase
• Exceptions: age >40 or family history of HCC, liver biopsy showing significant necroinflammation

Treatment Endpoints and Duration

HBeAg-Positive Disease:

• Goal: HBeAg seroconversion (loss of HBeAg, gain of anti-HBe) + HBV DNA suppression
• For oral nucleos(t)ides: treat until HBeAg seroconversion, then continue for at least 12 additional months of consolidation therapy before considering discontinuation
• Ultimate goal: HBsAg loss (functional cure), which occurs rarely but is the ideal endpoint

HBeAg-Negative Disease:

• No defined endpoint with oral therapy; long-term (potentially indefinite) therapy typically required
• HBsAg loss is very rare; treatment discontinuation often leads to relapse
• Some guidelines consider stopping in selected non-cirrhotic patients after prolonged virologic suppression

PEG IFN:

• Fixed 48-week course; no indefinite dosing

Special Populations

Children (age 2 to <18 years)

• HBeAg-positive with detectable HBV DNA + elevated ALT: treat
• HBeAg-positive with normal ALT: do NOT treat
• Approved first-line agents:
  • PEG IFN alpha-2a: age ≥5 years (approved for hepatitis C but used off-label for B)
  • Entecavir: age ≥2 years
  • Tenofovir: age ≥2 years

HIV-HBV Co-infection

• TDF or TDF/emtricitabine (Truvada) are excellent choices for dual HIV+HBV coverage
• TAF is preferred over TDF due to better renal/bone safety profile
• Treat for both HIV and HBV even if HIV treatment criteria not yet met

Cirrhosis

• Compensated or decompensated cirrhosis: PEG IFN is contraindicated - risk of sepsis and decompensation
• Preferred: Entecavir or Tenofovir (very favorable resistance profile)
• Liver transplantation: Prevention of recurrent HBV = short-term IV HBIG (5-7 days) + lifelong low-resistance oral entecavir, TDF, or TAF
  • Combination HBIG + oral agent recommended for high-risk patients (HDV-HBV or HIV-HBV co-infection, non-adherent patients)
  • Patients receiving livers from anti-HBc-positive donors: lifelong oral agent therapy (without HBIG)

Immunosuppression / Chemotherapy

• HBV reactivation risk is high when immunosuppressive therapy is withdrawn
• Risk stratification:
  • Highest risk: B cell-depleting agents (e.g., rituximab), anthracycline derivatives, moderate/high-dose corticosteroids ≥4 weeks
  • Moderate risk: TNF-alpha inhibitors, cytokine/integrin inhibitors, tyrosine kinase inhibitors, low-dose corticosteroids ≥4 weeks
• Management: Preemptive antiviral therapy with entecavir or tenofovir BEFORE initiation of chemotherapy (preferred over treating after reactivation)
• Prophylaxis duration: generally continue for 12 months after cessation of immunosuppressive therapy (longer for B cell-depleting agents)

Pregnancy

• TDF is the preferred oral antiviral in pregnancy (Category B; extensive safety data)
• PEG IFN is contraindicated in pregnancy
• For HBsAg-positive mothers with high HBV DNA (>200,000 IU/mL), TDF in the 3rd trimester reduces mother-to-child transmission
• Newborns of HBsAg-positive mothers receive HBIG + hepatitis B vaccine at birth

Summary Table: First-Line Agents Comparison

Key Points

1. First-line options: Entecavir, TDF, TAF, or PEG IFN - oral agents generally preferred
2. TAF preferred over TDF in patients with renal or bone concerns, and in HIV co-infection
3. Entecavir preferred in cirrhosis (along with tenofovir); very high barrier to resistance
4. PEG IFN offers finite treatment and off-therapy immune control but is contraindicated in cirrhosis and pregnancy
5. Lamivudine and adefovir are no longer first-line due to high resistance rates
6. Indefinite therapy is typically required for HBeAg-negative CHB with oral agents; HBeAg-positive CHB treated until seroconversion + 12-month consolidation
7. Functional cure (HBsAg loss) remains the ultimate but rarely achieved goal with current therapies

Indications to Start Treatment for Chronic Hepatitis B

Harrison's Principles of Internal Medicine, 22nd Edition (2025) - Chapter 352

General Principles

• Inactive "non-replicative" HBsAg carriers: undetectable HBeAg + normal ALT + HBV DNA ≤10³ IU/mL (documented serially over time)
• HBeAg-positive patients in the immune-tolerant phase (high HBV DNA + normal ALT) - these patients merit monitoring with HBV DNA and ALT at least every 6 months

• Any patient with compensated cirrhosis and detectable HBV DNA
• Decompensated cirrhosis - treatment should be carefully considered (with oral agents only)

Table 352-4: Recommendations for Treatment of Chronic Hepatitis B

HBeAg-POSITIVE Patients

HBeAg-NEGATIVE Patients

HBeAg-Positive: Detailed Criteria

• AASLD threshold: HBV DNA >2 × 10⁴ IU/mL + ALT >2× ULN → TREAT
• EASL threshold (slightly lower): HBV DNA >2 × 10³ IU/mL + ALT above ULN → TREAT
• For HBeAg-positive patients with ALT ≤2× ULN, sustained responses are not likely, so treatment is generally withheld - EXCEPT in patients with:
  • Age >40 years
  • Family history of cirrhosis or HCC
  • Extrahepatic manifestations of hepatitis B (e.g., polyarteritis nodosa, glomerulonephritis)
  • History of prior treatment
  • Liver biopsy showing moderate-to-severe inflammation or fibrosis

HBeAg-Negative: Detailed Criteria

• AASLD/EASL: HBV DNA >2 × 10³ IU/mL + ALT >ULN → TREAT
• Inactive carriers (HBV DNA ≤10³-2×10⁴ IU/mL, normal ALT) do not require treatment

Special Populations: Additional Indications

Cirrhosis

• Compensated or decompensated cirrhosis with any detectable HBV DNA → treat with oral agents (entecavir or tenofovir); PEG IFN is contraindicated due to risk of sepsis and decompensation

Immunosuppression / Chemotherapy

• Preemptive antiviral therapy is indicated BEFORE initiating:
  • B cell-depleting agents (e.g., rituximab) - highest risk
  • Anthracycline derivatives - highest risk
  • Moderate/high-dose corticosteroids ≥4 weeks - highest risk
  • TNF-alpha inhibitors, cytokine/integrin inhibitors, tyrosine kinase inhibitors, low-dose corticosteroids ≥4 weeks - moderate risk
• Entecavir or tenofovir are preferred for prophylaxis (over lamivudine)

HIV-HBV Co-infection

• Treat for both HBV and HIV even if HIV treatment criteria not yet met

Children (age 2-<18 years)

• HBeAg-positive with detectable HBV DNA + elevated ALT → treat
• HBeAg-positive with normal ALT → do NOT treat

Pregnancy

• HBsAg-positive mothers with HBV DNA >200,000 IU/mL: TDF in the 3rd trimester to reduce mother-to-child transmission; newborns receive HBIG + HBV vaccine at birth

Key Threshold Summary

Note: EASL thresholds are slightly more liberal (treat at lower HBV DNA and lower ALT elevations in HBeAg-positive disease)

HBV DNA Threshold in HBeAg-Negative Chronic Hepatitis B

Harrison's Principles of Internal Medicine, 22nd Edition — Table 352-4

Treat When:

HBV DNA > 2 × 10³ IU/mL (i.e., >2,000 IU/mL) + ALT > ULN

Do NOT Treat (Inactive Carrier State):

HBV DNA ≤ 2 × 10⁴ IU/mL + ALT ≤ ULN = Inactive carrier - no treatment necessary

Summary Table (HBeAg-Negative):

Key Point:

Petroleum Product-Related Hepatocellular Carcinoma

1. Key Petroleum/Industrial Chemicals and Liver Cancer

A. Vinyl Chloride Monomer (VCM) - IARC Group 1 Carcinogen

• Metabolized by CYP2E1 to the reactive intermediate 2-chloroethylene oxide (chloroethylene oxide), which forms DNA adducts
• Alcohol synergistically enhances this carcinogenicity by inducing CYP2E1
• Causes a ras-p21 mutation (detectable in serum of 80% of vinyl chloride-induced angiosarcoma patients) and TP53 mutations

• Nodular subcapsular fibrosis, sinusoidal dilatation, peliosis hepatis, periportal fibrosis
• Toxicant-associated steatohepatitis (TASH) in ~80% of exposed non-obese workers (>50% with significant fibrosis)
• Hepatic angiosarcoma - the classic and most well-established neoplastic outcome
  • First identified as occupationally related in 1974 (tire manufacturing workers, Kentucky)
  • Mean latency: 25 years after exposure
  • Risk correlates with duration and extent of contact
  • History of VCM exposure found in 15-25% of all hepatic angiosarcoma cases in the late 1970s
  • Strict hygienic measures post-1974 markedly reduced incidence

• Controversial - this is an area of ongoing debate
• Large American and European multicenter mortality cohort studies showed increased mortality from "primary liver cancer" in VCM-exposed workers
• A meta-analysis (Lotti, 2017, Liver International [PMID: 28063180]) concluded: small excess risk of primary liver cancer, but misclassification of angiosarcoma as HCC could not be ruled out
• A European subcohort study with 10 verified HCC cases did show an exposure-response trend with duration of employment and cumulative VCM exposure
• The current consensus: VCM probably causes HCC in addition to angiosarcoma, especially at high cumulative exposures and when combined with viral hepatitis (additive/multiplicative interaction)

B. Aflatoxin B1 - IARC Group 1 Carcinogen (Most Potent Known Hepatocarcinogen)

• Converted by hepatic CYP enzymes (P-450) to the reactive aflatoxin B1-8,9-epoxide, which forms DNA adducts
• Causes a highly specific TP53 mutation: arginine → serine at codon 249 (R249S) - this hotspot mutation is a molecular fingerprint of aflatoxin exposure (Harrison's 22E, Chapter 87)
• This specific mutation is also detectable in patients with HBV + aflatoxin co-exposure

• Accounts for 3-20% of global liver cancer cases; up to 40% in sub-Saharan Africa
• Synergistic with HBV: Aflatoxin + HBV co-exposure increases HCC risk multiplicatively (far beyond either alone)
• Estimated to be responsible for 25,000-155,000 HCC cases globally per year

C. Polycyclic Aromatic Hydrocarbons (PAHs) - Core Petroleum Carcinogens

• Indirect-acting carcinogens requiring CYP-mediated metabolic activation (epoxidation)
• Form bulky DNA adducts leading to TP53 and RAS mutations
• Polymorphisms in CYP enzymes (especially CYP1A1, CYP1B1) influence individual cancer risk

• While PAHs are best known for causing lung cancer (via inhalation), hepatic first-pass metabolism of ingested/absorbed PAHs leads to direct hepatic DNA damage
• Occupational exposure in petroleum refinery workers, coke oven workers, asphalt workers, chimney sweeps is associated with elevated liver cancer risk

D. Arsenic - Naturally Occurring Petroleum-Industry Contaminant

• Present in coal combustion byproducts, petroleum refining residues, metal smelting
• IARC Group 1 carcinogen for multiple cancers including liver (HCC and angiosarcoma)
• Causes hepatic fibrosis, non-cirrhotic portal hypertension, and HCC
• Mechanism: oxidative stress, DNA methylation disruption, inhibition of DNA repair
• Robbins Basic Pathology lists arsenic alongside vinyl chloride as a hepatic carcinogen

E. Other Petroleum-Industry Chemical Carcinogens

2. Molecular Pathogenesis - How Petroleum Chemicals Cause HCC

Chemical carcinogen (PAH, vinyl chloride, aflatoxin)
         ↓
CYP450-mediated metabolic activation → reactive electrophile
         ↓
DNA adduct formation → strand breaks, mutations
         ↓
Key driver mutations: TP53 (R249S for aflatoxin), RAS, TERT promoter
         ↓
Chronic hepatocyte injury → inflammation → oxidative stress → fibrosis
         ↓
Cirrhosis → dysplastic nodules (LGDN → HGDN) → HCC

• The chemical carcinogen acts as initiator (mutagenic DNA damage)
• Sustained hepatocyte proliferation (from ongoing toxin exposure, alcohol, viral hepatitis) acts as promoter
• Co-exposure to HBV/HCV dramatically amplifies risk through this dual mechanism

3. High-Risk Occupational Groups

• PVC / plastic manufacturing workers (vinyl chloride exposure)
• Petroleum refinery workers (PAHs, benzene, arsenic)
• Coke oven and coal tar workers (PAHs)
• Rubber industry workers (vinyl chloride, benzene)
• Agricultural workers (aflatoxin, organochlorine pesticides)
• Waste disposal and chemical processing workers (organic solvents, N-nitrosamines)
• Metal smelting workers (arsenic, cadmium)

4. Surveillance Recommendations

• Workers previously exposed to vinyl chloride should undergo regular clinical examinations for early detection of liver tumors
• Those with known chronic liver disease or high cumulative exposure should undergo regular hepatic imaging
• Workers in PVC plants should have regular liver biochemical tests; persistent abnormalities warrant removal from workplace exposure

Summary

Petroleum products contain multiple classes of hepatocarcinogens. Vinyl chloride (PVC industry) is the most well-characterized petroleum-related liver carcinogen - it primarily causes hepatic angiosarcoma (IARC Group 1, latency ~25 years), with growing evidence that it also causes HCC, especially with concurrent viral hepatitis. PAHs from crude oil and refinery processes cause DNA adduct-mediated mutagenesis. Aflatoxin B1, while not a petroleum product itself, is the most potent known chemical hepatocarcinogen and acts synergistically with HBV via the hallmark TP53 R249S mutation. Arsenic and PCBs, encountered in petroleum and heavy industry settings, are additional Group 1 hepatic carcinogens. All these agents share the common mechanism of CYP450-dependent metabolic activation, reactive electrophile formation, and driver gene mutations leading to HCC.

• Harrison's Principles of Internal Medicine, 22E (2025), Chapter 87 (HCC: Epidemiology, Risk Factors, Molecular Pathogenesis)
• Sleisenger & Fordtran's Gastrointestinal and Liver Disease (Vinyl Chloride chapter)
• Robbins & Kumar Basic Pathology (Chemical Carcinogens, Indirect-Acting Agents)
• Lotti M. Vinyl chloride and HCC/cirrhosis (Meta-Analysis). Liver Int 2017 [PMID: 28063180]
• Barsouk A et al. Chemical Risk Factors of Primary Liver Cancer. Hepatic Med 2020 [PMID: 33447099]